Clinical trial
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to…
NCT00161564 · Weill Medical College of Cornell University, Other · Withdrawn
Key facts
| NCT number | NCT00161564 |
|---|---|
| Title | A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone |
| Official title | A Randomized Trial Comparing Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine,and Prednisone) in Subjects With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Idiopathic Thrombocytopenic Purpura (ITP) |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 0 |
| Start date | Feb 1, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Jul 17, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: